Bench to bedside: Mechanistic principles of targeting the RAF kinase in melanoma

International Journal of Dermatology

Volumn 53, Issue 12, 2014, Pages 1428-1433

  Rajakulendran, Thanashan ^a   Adam, David N ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; COBIMETINIB; DABRAFENIB; DACARBAZINE; ENCORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADVANCED CANCER; ALLOSTERISM; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; DIMERIZATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG TARGETING; ENZYME CONFORMATION; HUMAN; MELANOMAGENESIS; METASTATIC MELANOMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG DEVELOPMENT; DRUG RESISTANCE; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84914095968     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12724     Document Type: Review

References (36)

1. Walkington LA, Lorigan P, Danson SJ. Advances in the treatment of late stage melanoma. BMJ 2013; 346: f1265.
2. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol 2013; 14: e60-e69.
3. Tsao H, Chin L, Garraway LA, et al. Melanoma: from mutations to medicine. Genes Dev 2012; 26: 1131-1155.
4. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? J Skin Cancer 2013; 2013: 735282.
5. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
6. Rosenblum JS, Nomanbhoy TK, Kozarich JW. Functional interrogation of kinases and other nucleotide-binding proteins. FEBS Lett 2013; 587: 1870-1877.
7. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 103-119.
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
9. Udell CM, Rajakulendran T, Sicheri F, et al. Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci 2011; 68: 553-565.
10. Hoeflich KP, Jaiswal B, Davis DP, et al. Inducible BRAF suppression models for melanoma tumorigenesis. Methods Enzymol 2008; 439: 25-38.
11. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
12. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003; 121: 1160-1162.
13. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5: 875-885.
14. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198-5202.
15. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23: 6292-6298.
16. Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107: 14903-14908.
17. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109: 275-282.
18. Duffy MJ. The war on cancer: are we winning? Tumour Biol 2013; 34: 1275-1284.
19. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
20. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-137.
21. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
22. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10: 6388S-6392S.
23. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
24. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-215.
25. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046.
26. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
27. Nazarian RM, Prieto VG, Elder DE, et al. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 2010; 37(Suppl. 1): 41-47.
28. Antony R, Emery CM, Sawyer AM, et al. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res 2013; 73: 4840-4851.
29. Rajakulendran T, Sahmi M, Lefrancois M, et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009; 461: 542-545.
30. Lavoie H, Thevakumaran N, Gavory G, et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 2013; 9: 428-436.
31. Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 2013; 49: 751-758.
32. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
33. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
34. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 989-1000.
35. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
36. Jang S, Atkins MB. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 2014; 95: 24-31.